Structure-Functional Analysis of Human Cytochrome P450 2C8 Using Directed Evolution

被引:6
|
作者
Lee, Rowoon [1 ]
Kim, Vitchan [1 ]
Chun, Youngjin [2 ]
Kim, Donghak [1 ]
机构
[1] Konkuk Univ, Dept Biol Sci, Seoul 05029, South Korea
[2] Chung Ang Univ, Coll Pharm, Seoul 06974, South Korea
基金
新加坡国家研究基金会;
关键词
P450; directed evolution; luciferin; paclitaxel; arachidonic acid; mass spectrometry; ARACHIDONIC-ACID; BINDING; EXPRESSION; ENZYMES; P4502C8; STEPS; 2A6; 1A2;
D O I
10.3390/pharmaceutics13091429
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The human genome includes four cytochrome P450 2C subfamily enzymes, and CYP2C8 has generated research interest because it is subject to drug-drug interactions and various polymorphic outcomes. To address the structure-functional complexity of CYP2C8, its catalytic activity was studied using a directed evolution analysis. Consecutive rounds of random mutagenesis and screening using 6-methoxy-luciferin produced two mutants, which displayed highly increased luciferase activity. Wild-type and selected mutants were expressed on a large scale and purified. The expression levels of the D349Y and D349Y/V237A mutants were similar to 310 and 460 nmol per liter of culture, respectively. The steady-state kinetic analysis of paclitaxel 6 alpha-hydroxylation showed that the mutants exhibited a 5-7-fold increase in k(cat) values and a 3-5-fold increase in catalytic efficiencies (k(cat)/K-M). In arachidonic acid epoxidation, two mutants exhibited a 30-150-fold increase in k(cat) values and a 40-110-fold increase in catalytic efficiencies. The binding titration analyses of paclitaxel and arachidonic acid showed that the V237A mutation had a lower K-d value, indicating a tighter substrate-binding affinity. The structural analysis of CYP2C8 indicated that the D349Y mutation was close enough to the putative binding domain of the redox partner; the increase in catalytic activity could be partially attributed to the enhancement of the P450 coupling efficiency or electron transfer.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Cytochrome P450 2C8 and Drug Metabolism
    Lv, Xiaoping
    Zhong, Fangfang
    Tan, Xiangshi
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2013, 13 (18) : 2241 - 2253
  • [2] Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8
    Hualin Jiang
    Fangfang Zhong
    Lu Sun
    Weiyue Feng
    Zhong-Xian Huang
    Xiangshi Tan
    Amino Acids, 2011, 40 : 1195 - 1204
  • [3] Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8
    Jiang, Hualin
    Zhong, Fangfang
    Sun, Lu
    Feng, Weiyue
    Huang, Zhong-Xian
    Tan, Xiangshi
    AMINO ACIDS, 2011, 40 (04) : 1195 - 1204
  • [4] MicroRNAs 103 and 107 regulate the expression of Human Cytochrome P450 2C8
    Zhang, Shuyun
    Surapureddi, Sailesh
    Goldstein, Joyce A.
    FASEB JOURNAL, 2011, 25
  • [5] Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions
    Backman, Janne T.
    Filppula, Anne M.
    Niemi, Mikko
    Neuvonen, Pertti J.
    PHARMACOLOGICAL REVIEWS, 2016, 68 (01) : 168 - 241
  • [6] Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies
    Daily, Elizabeth B.
    Aquilante, Christina L.
    PHARMACOGENOMICS, 2009, 10 (09) : 1489 - 1510
  • [7] Examination of 209 drugs for inhibition of cytochrome p450 2C8
    Walsky, RL
    Gaman, EA
    Obach, RS
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (01): : 68 - 78
  • [8] Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8)
    Ma, Yong
    Fu, Yu
    Khojasteh, S. Cyrus
    Dalvie, Deepak
    Zhang, Donglu
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (21) : 8691 - 8705
  • [9] In vitro modulatory effects of flavonoids on human cytochrome P450 2C8 (CYP2C8)
    Chia Yong Pang
    Joon Wah Mak
    Rusli Ismail
    Chin Eng Ong
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2012, 385 : 495 - 502
  • [10] In vitro modulatory effects of flavonoids on human cytochrome P450 2C8 (CYP2C8)
    Pang, Chia Yong
    Mak, Joon Wah
    Ismail, Rusli
    Ong, Chin Eng
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2012, 385 (05) : 495 - 502